FDA Grants Breakthrough Device Status for MediBeacon's Transde...
ST. LOUIS, Oct. 22, 2018 /PRNewswire-AsiaNet/-- -- MediBeacon's Breakthrough Device is Intended to Measure GFR in Patients with Impaired or Normal Kidney FunctionMediBeacon Inc. (http://www.medibeacon.com/ ), whose largest shareholder is Pansend Life Sciences of HC2 Holdings, Inc. (NYSE MKT...
Read more https://view-release/?pr-id=75846